Clinical Trial

Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 12, 2025 (before its estimated February 28, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this revised Phase IIa study is to demonstrate safety of INS018\_055 over 12 weeks in adults with Idiopathic Pulmonary Fibrosis (IPF).
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2023-07-27; most recent amendment 2025-11-10.
Status change: Not Yet Recruiting → Recruiting 2023-12-18
Trial Details
NCT Number NCT05975983
Lead Sponsor InSilico Medicine Hong Kong Limited
Conditions Idiopathic Pulmonary Fibrosis (IPF)
Enrollment 40 participants
Start Date 2024-02-08
Primary Completion 2026-02-28 (estimated)
Study Completion 2026-02-28 (estimated)
Updated on ClinicalTrials.gov 2025-11-12